Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat
- 1 August 1970
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 22 (8), 553-560
- https://doi.org/10.1111/j.2042-7158.1970.tb10570.x
Abstract
Mean arterial blood pressure was recorded through in-dwelling arterial catheters in conscious normotensive Sprague-Dawley rats. L-3,4-Dihydroxyphenylalanine (L-dopa) was given in various doses intraperitoneally, alone and after pretreatment with an inhibitor of dopa decarboxylase, α-hydrazino-α-methyl-β-(3,4-dihydroxyphenyl) propionic acid (MK 485) or seryl-2,3,4-trihydroxybenzylhydrazine (Ro 4–4602). L-Dopa (50 mg/kg) produced a hypertensive response which was abolished by MK 485 (100 mg/kg). A larger dose of L-dopa (200 mg/kg) after MK 485 caused a significant lowering of blood pressure after 15–20 min. After Ro 4–4602 (400 + 200 mg/kg), injection of L-dopa (200 mg/kg) had no significant effect on blood pressure. The hypotensive response to L-dopa (200 mg/kg) after MK 485 was not influenced by the central dopamine receptor blocking agent, spiroperidol (0.1 mg/kg), but could be completely inhibited by the dopamine β-hydroxylase inhibitor, bis-(4-methyl-1-homopiperazinyl-thiocarbonyl)disulphide (FLA 63) (40 mg/kg). Pretreatment with protripty-line (10 mg/kg) completely blocked the hypotensive effect of L-dopa after MK 485. In correlative biochemical experiments, levels of noradrenaline and dopamine were determined in brain, heart and femoral muscle. L-Dopa (200 mg/kg) alone caused a significant increase of dopamine levels in all tissues. After MK 485 and Ro 4–4602 L-dopa did not significantly increase the levels of dopamine in heart or femoral muscle; however, brain dopamine levels were increased more than after L-dopa alone, but brain dopamine levels after Ro 4–4602 were significantly lower than after MK 485, indicating some central decarboxylase inhibition by Ro 4–4602. L-Dopa alone reduced the noradrenaline content of the heart and this effect was prevented by MK 485 and Ro 4–4602. The results show that decarboxylation of L-dopa in both the central and the peripheral nervous system leads to an increase in blood pressure. Decarboxylation of L-dopa in the central nervous system only results in a hypotensive response, provided that high amounts of dopamine are formed in the brain. This effect was prevented by an inhibitor of dopamine β-hydroxylase but not by a dopamine receptor blocker. Therefore, a central noradrenaline mechanism seems to be involved. The presence of an intact membrane pump in noradrenaline neurons may be essential since protriptyline also blocked the hypotensive action.Keywords
This publication has 21 references indexed in Scilit:
- Behavioral and biochemical effects ofl-DOPA after peripheral decarboxylase inhibitionBrain Research, 1969
- Peripheral factors in the mediation of the effects of L-dopa on locomotor activityJournal of Pharmacy and Pharmacology, 1969
- Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanineJournal of Pharmacy and Pharmacology, 1969
- L-DOPA IN POSTENCEPHALITIC PARKINSONISMThe Lancet, 1969
- Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylaseJournal of Pharmacy and Pharmacology, 1968
- Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral DecarboxylaseNature, 1967
- Evidence for a role of dopamine in extrapyramidal functionsJournal of Neural Transmission, 1964
- In‐Vivo Decarboxylation of α‐Methyl DOPA and α‐Methyl MetatyrosineActa Physiologica Scandinavica, 1962
- The decarboxylation of amino acids related to tyrosine and their awakening action in reserpine‐treated miceThe Journal of Physiology, 1960
- A Method for the Fluorimetric Determination of Adrenaline and Noradrenaline in Tissues.1Acta Physiologica Scandinavica, 1958